Posted by Michael Wonder on 12 Apr 2023
Takeda receives FDA approval to expand the use of Hyqvia to treat primary immunodeficiency in children
11 April 2023 - Approval supported by pivotal Phase 3 study that demonstrated reliable infection protection in children 2-16 years pld.
Takeda today announced that the US FDA has approved a supplemental biologics license application to expand the use of Hyqvia to treat primary immunodeficiency in children 2-16 years old.
